At a glance
- Originator Hisamitsu Pharmaceutical
- Class Analgesics; Anti-inflammatories; Antirheumatics; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 09 Mar 1999 No-Development-Reported for Rheumatoid arthritis in Japan (PO)
- 05 Dec 1996 New profile
- 05 Dec 1996 Preclinical development for Rheumatoid arthritis in Japan (PO)